CTLA4 and neoplasm: For CTLA-4 blockade, B. fragilis can induce Th1-weighted systemic immunity, as shown in germ-free or antibiotic-treated mice, anti-CTLA-4 therapy had no anti-tumor effect until B. fragilis bolstering Il-12 production was introduced [248].